Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement

Ann Intern Med. 2014 Dec 2;161(11):819-26. doi: 10.7326/M14-1884.

Abstract

Description: Update of the 1996 U.S. Preventive Services Task Force (USPSTF) recommendation on aspirin prophylaxis in pregnancy.

Methods: The USPSTF reviewed the evidence on the effectiveness of low-dose aspirin in preventing preeclampsia in women at increased risk and in decreasing adverse maternal and perinatal health outcomes, and assessed the maternal and fetal harms of low-dose aspirin during pregnancy.

Population: This recommendation applies to asymptomatic pregnant women who are at increased risk for preeclampsia and who have no prior adverse effects with or contraindications to low-dose aspirin.

Recommendation: The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. (B recommendation).

Publication types

  • Practice Guideline
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aspirin / administration & dosage*
  • Aspirin / adverse effects
  • Biomedical Research
  • Cost of Illness
  • Female
  • Humans
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Pre-Eclampsia / mortality
  • Pre-Eclampsia / prevention & control*
  • Pregnancy
  • Pregnancy Outcome
  • Risk Assessment

Substances

  • Platelet Aggregation Inhibitors
  • Aspirin